Hims & Hers has been an incredible stock to own over the last few years, making shareholders rich. It has $2 billion in ...

The healthcare company is experiencing excellent sales growth, but investors are concerned about its longer-term prospects.

Hims & Hers Health is upgraded to a speculative Buy after a 20% drop, with growth potential in GLP-1 sales outweighing key ...

At $13.6 billion in market capitalization, Hims & Hers stock costs a pricey 70 times trailing earnings. It's even more ...

The telehealth-consultation platform posted an increase in profit and revenue for the second quarter on growth in subscribers ...

Shares of Hims & Hers Inc. fell after hours on Monday after the wellness and telehealth platform’s third-quarter forecast ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending ...

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

Hims & Hers Health showed a sharper-than-expected revenue hiccup in Q2, sending the stock down. Click here to find out why ...

Hims & Hers Health, a telehealth platform that sells knockoffs of popular weight loss drugs, sank in after-hours trading ...